Literature DB >> 17582511

Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia.

Chi-Un Pae1, Tae-Suk Kim, Ashwin A Patkar, Jung-Jin Kim, Chang-Uk Lee, Soo-Jung Lee, Tae-Youn Jun, Chul Lee, In-Ho Paik.   

Abstract

There has been increasing evidence that the alteration of antioxidant enzymes such as manganese superoxide dismutase (MnSOD) might be implicated in the development of schizophrenia and/or tardive dyskinesia (TD). This study investigated the association of a MnSOD gene (MnSOD) polymorphism (Ala-9Val) with schizophrenia as well as its involvement in TD. Patients with schizophrenia (n=262) and healthy controls (n=263) were enrolled in this study and genotyped by a polymerase chain reaction-based method. The distribution of the MnSOD genotypes and alleles was not significantly different between patients and controls. Logistic regression analysis also failed to reveal any association between MnSOD genotypes and TD. Taken together, these results suggest that the MnSOD polymorphism does not contribute to the development of schizophrenia and/or TD, at least in the Korean population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17582511     DOI: 10.1016/j.psychres.2006.04.011

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

Review 1.  Genetic association studies of antioxidant pathway genes and schizophrenia.

Authors:  Kodavali V Chowdari; Mikhil N Bamne; Vishwajit L Nimgaonkar
Journal:  Antioxid Redox Signal       Date:  2010-11-01       Impact factor: 8.401

Review 2.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 3.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

4.  Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.

Authors:  Xiang Y Zhang; Da C Chen; Mei H Xiu; Fu D Yang; Yunlong Tan; Xingguang Luo; Lingjun Zuo; Therese A Kosten; Thomas R Kosten
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

5.  Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Marko Saje; Katja Goričar; Vita Dolžan; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Neurochem Res       Date:  2012-12-02       Impact factor: 3.996

Review 6.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

Review 7.  Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives.

Authors:  Evgeny A Ermakov; Elena M Dmitrieva; Daria A Parshukova; Daria V Kazantseva; Alisa R Vasilieva; Liudmila P Smirnova
Journal:  Oxid Med Cell Longev       Date:  2021-01-23       Impact factor: 6.543

8.  Meta-Analyses of Manganese Superoxide Dismutase Activity, Gene Ala-9Val Polymorphism, and the Risk of Schizophrenia.

Authors:  Dong-Fang Wang; Bing Cao; Mei-Yan Xu; Ya-Qiong Liu; Lai-Lai Yan; Rong Liu; Jing-Yu Wang; Qing-Bin Lu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

Review 9.  Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.

Authors:  Mujeeb U Shad
Journal:  Behav Sci (Basel)       Date:  2021-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.